Have a feature idea you'd love to see implemented?
Let us know!
IMNN Imunon Inc
Price (delayed)
$0.8058
Market cap
$11.68M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.89
Enterprise value
$2.64M
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of
Highlights
The company's EPS rose by 42% YoY
IMNN's debt is down by 27% YoY and by 9% from the previous quarter
The equity has soared by 119% since the previous quarter but it has dropped by 55% year-on-year
Imunon's quick ratio has soared by 80% from the previous quarter but it has decreased by 48% YoY
The company's gross profit has shrunk by 100% YoY
Imunon's revenue has plunged by 100% YoY
Key stats
What are the main financial stats of IMNN
Market
Valuations
Earnings
Shares outstanding
14.5M
Market cap
$11.68M
Enterprise value
$2.64M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.42
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$19.45M
EBIT
-$20.73M
EBITDA
-$20.04M
Free cash flow
-$18.22M
Per share
Balance sheet
Liquidity
EPS
-$1.89
EPS diluted
-$1.89
Free cash flow per share
-$1.26
Book value per share
$0.57
Revenue per share
$0
TBVPS
$1
Total assets
$14.39M
Total liabilities
$6.2M
Debt
$1.27M
Equity
$8.19M
Working capital
$7.09M
Debt to equity
0.15
Current ratio
2.3
Quick ratio
1.89
Net debt/EBITDA
0.45
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-129%
Return on equity
-230.1%
Return on invested capital
-423.5%
Return on capital employed
-231.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMNN stock price
How has the Imunon stock price performed over time
Intraday
-1.13%
1 week
-5.67%
1 month
-2.79%
1 year
11.45%
YTD
18.5%
QTD
-23.98%
Financial performance
How have Imunon's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$20.95M
Net income
-$19.45M
Gross margin
N/A
Net margin
N/A
The company's gross profit has shrunk by 100% YoY
Imunon's revenue has plunged by 100% YoY
The net income has grown by 30% YoY but it has contracted by 8% from the previous quarter
IMNN's operating income is down by 5% QoQ but it is up by 4.7% YoY
Growth
What is Imunon's growth rate over time
Valuation
What is Imunon stock price valuation
P/E
N/A
P/B
1.42
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 42% YoY
The equity has soared by 119% since the previous quarter but it has dropped by 55% year-on-year
IMNN's price to book (P/B) is 21% lower than its last 4 quarters average of 1.8 but 2.1% higher than its 5-year quarterly average of 1.4
Imunon's revenue has plunged by 100% YoY
Efficiency
How efficient is Imunon business performance
The ROE has plunged by 97% YoY and by 39% from the previous quarter
Imunon's return on assets has shrunk by 61% YoY and by 26% QoQ
IMNN's ROIC has shrunk by 52% QoQ
Dividends
What is IMNN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMNN.
Financial health
How did Imunon financials performed over time
The total assets is 132% more than the total liabilities
Imunon's quick ratio has soared by 80% from the previous quarter but it has decreased by 48% YoY
The current ratio has soared by 52% from the previous quarter but it has contracted by 44% YoY
IMNN's debt is 85% less than its equity
The equity has soared by 119% since the previous quarter but it has dropped by 55% year-on-year
IMNN's debt to equity has shrunk by 59% QoQ but it has soared by 50% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.